Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

Covid vaccine makers Pfizer, BioNTech and Moderna are being sued for allegedly copying messenger RNA (mRNA) technology ...

Filed in a Delaware federal court, the lawsuits claim the companies copied technology developed by Bayer's subsidiary, ...

Bayer's agrochemicals unit Monsanto has filed lawsuits in the US against the manufacturers of mRNA-based COVID-19 vaccines, ...

An update from Moderna ( ($MRNA) ) is now available. In a January 5, 2026 letter to shareholders, Moderna reviewed a challenging 2025 operating ...

Bayer has filed patent infringement lawsuits against COVID-19 vaccine makers Pfizer, BioNTech, Moderna, and Johnson & Johnson ...

The JN.1 Novavax vaccine is an alternative to the LP.8.1 Pfizer-BioNTech and Moderna vaccines that were rolled out in October ...

Moderna (MRNA) has been quietly grinding higher, with the stock up roughly 11% over the past month and 12% in the past 3 ...

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Moderna (MRNA) provided an update on regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 ...